Why Warning-Defect Cases Turn on a Doctrine, Not a Defect
In a prescription-drug or medical-device case, the failed-warning theory almost never dies on whether the warning was inadequate. It dies on the learned-intermediary doctrine. Most states hold that a manufacturer discharges its duty to warn by giving an adequate warning to the prescribing physician, not to the patient, on the theory that the doctor stands between the product and the patient and makes an independent judgment about whether to prescribe it. For plaintiff's counsel, that means the entire warning-defect case runs through the prescriber, and the manufacturer's defense is built to make the prescriber the last word.
Understanding how the doctrine actually operates is what separates a warning claim that survives summary judgment from one that does not. The defect in the label is often easy to show. The hard part is proving that a better warning would have changed what the physician did, and then keeping the manufacturer from hiding behind the physician entirely.
The Causation Battleground
Once the doctrine applies, warning causation becomes the fight. The manufacturer will depose the prescriber and try to extract testimony that a stronger warning would not have altered the prescribing decision, that the doctor already knew the risk, or that the doctor does not read package inserts. Any of those answers can sink the case, because it severs the link between the inadequate warning and the injury.
The plaintiff's preparation has to start before that deposition. Counsel needs the prescriber's actual knowledge at the time of prescribing, the sources the physician relied on, and whether the specific risk that materialized was one the physician would have weighed differently with a complete warning. A physician who concedes she would have disclosed a black-box risk to the patient, or chosen a different agent, gives the plaintiff the causal bridge. A physician who says the warning made no difference hands the defense a directed verdict. The deposition is not a formality; it is frequently the entire case.
There is a recurring defense wrinkle worth flagging. Some courts have entertained the idea that a confident prescriber who says he would prescribe again regardless defeats warning causation as a matter of law. Plaintiff's counsel should be ready to argue that hindsight confidence, offered after the injury and after litigation began, is not the same as the decision the physician would have made with an adequate warning at the time. The question is contemporaneous, not retrospective.
Where the Doctrine Does Not Reach
The learned-intermediary shield has real edges, and the exceptions are where warning cases get their leverage.
- Direct-to-consumer advertising. New Jersey's Supreme Court, in Perez v. Wyeth Laboratories, held that when a manufacturer markets a prescription product straight to consumers, it cannot rely unqualifiedly on the learned-intermediary rule and may owe a duty to warn the patient directly. The doctrine's premise, that the patient learns of risk only through the doctor, breaks down when the company speaks to the patient over the doctor's head.
- Pharmacist knowledge of a patient-specific risk. Courts have recognized that the doctrine does not protect against a pharmacist who is aware of a patient-specific danger or fills a prescription containing an obvious error a competent pharmacist would catch. That is a narrower duty, but a live one.
- Contraceptives and mass-administered vaccines. Several jurisdictions carve out contraceptive products and vaccines given in mass clinics where no individualized physician counseling occurs. Without a true intermediary, the rationale for the shield disappears.
Whether any exception is available depends entirely on the governing state's law, so the first move in a warning file is choosing the forum and pinning down which version of the doctrine, and which exceptions, control.
The Coming Fight Over Algorithmic Prescribing
A newer question is starting to surface: what happens when an algorithm or clinical-decision tool sits between the manufacturer and the prescriber. Commentators have begun asking whether an artificial-intelligence system that recommends or screens prescriptions can be a learned intermediary, or whether its involvement instead breaks the chain and revives a direct duty to warn. No settled answer exists yet, but practitioners handling device and drug cases should preserve the software layer in discovery now, because the record will matter long before the doctrine catches up.
Building the Warning Case
Practical case-building on a warning-defect theory comes down to four moving parts, and they interact with the rest of a products file.
- The label history. Pull every version of the warning, the regulatory correspondence behind each change, and any internal signal the manufacturer had before it updated the language. A warning strengthened after the plaintiff's injury tells a story, subject to the usual subsequent-remedial-measure limits.
- The prescriber's file. Treat the prescribing physician as the central witness, not a bystander. Their contemporaneous knowledge decides causation.
- The marketing record. Where the manufacturer advertised to consumers, that record can open a DTC exception and reframe the duty. It also overlaps with the proof that surfaces in medical cases when the same product injured multiple patients.
- The design and manufacturing theory. A warning claim rarely travels alone. Pleading it alongside a design or manufacturing theory gives the jury a path even if the intermediary defense holds on the warning count.
The doctrine is not a wall. It is a chokepoint, and it channels the entire case through one witness and one decision. Plaintiff's counsel who understand that build the file around the prescriber from day one, and they keep the design and manufacturing theories alive so the case does not stand or fall on a single deposition answer. For a closer look at how these theories play out at trial, the recent rulings collected in our case-law coverage are the place to start.